|Other Names||Folate transporter 1, FOLT, Intestinal folate carrier 1, IFC-1, Placental folate transporter, Reduced folate carrier protein, RFC, Solute carrier family 19 member 1, SLC19A1, FLOT1, RFC1|
|Target/Specificity||The synthetic peptide sequence is selected from aa 206-218 of HUMAN SLC19A1|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transporter for the intake of folate. Uptake of folate in human placental choriocarcinoma cells occurs by a novel mechanism called potocytosis which functionally couples three components, namely the folate receptor, the folate transporter, and a V-type H(+)-pump.|
|Cellular Location||Membrane; Multi-pass membrane protein.|
|Tissue Location||Placenta, liver, and to a much smaller extent, in lung|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Transport of folate compounds into mammalian cells can occur via receptor-mediated (see MIM 136430) or carrier-mediated mechanisms. A functional coordination between these 2 mechanisms has been proposed to be the method of folate uptake in certain cell types. Methotrexate (MTX) is an antifolate chemotherapeutic agent that is actively transported by the carrier-mediated uptake system. RFC1 plays a role in maintaining intracellular concentrations of folate.
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Locke, A.E., et al. Genet. Epidemiol. 34(6):613-623(2010)
Adjei, A.A., et al. J Thorac Oncol 5(9):1346-1353(2010)
O'Byrne, M.R., et al. Birth Defects Res. Part A Clin. Mol. Teratol. 88(8):689-694(2010)
Tsunoda, A., et al. Ann. Oncol. (2010) In press :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.